Clinical Trial Results:
Effects of Mg-orotate on cardiocirculatory performance and adaptations at the muscular level: A double-blind, randomized, explorative, placebo-controlled, cross-over pilot study
Summary
|
|
EudraCT number |
2013-003418-42 |
Trial protocol |
DE |
Global end of trial date |
14 Feb 2018
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
01 Mar 2022
|
First version publication date |
01 Mar 2022
|
Other versions |
|
Summary report(s) |
Trial Report Summary |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
WOE_2013_TUE
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Wörwag Pharma GmbH & Co. KG
|
||
Sponsor organisation address |
Flugfeld-Allee 24, 71034 Böblingen, Germany,
|
||
Public contact |
Global Clinical Research, Wörwag Pharma GmbH & Co. KG, +49 70316204416, claudia.reule@woerwagpharma.com
|
||
Scientific contact |
Global Clinical Research, Wörwag Pharma GmbH & Co. KG, +49 70316204416, claudia.reule@woerwagpharma.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
13 Feb 2019
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
14 Feb 2018
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
14 Feb 2018
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
We performed an explorative pilot study in healthy individuals to address the question whether Mg-orotate might generally affect parameters of cardiorespiratory fitness during a 4 week training intervention period. We further analyzed skeletal muscle expression levels of a panel of genes known to be involved in structural, functional, and metabolic adaptation pathways in order to elucidate potential impacts of Mg-orotate supplementation on skeletal muscle remodeling processes.
|
||
Protection of trial subjects |
Before study initialization, favourable opinion was received from the Ethics Committee of the University Hospital of Tübingen and approval from the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte). This study is registered at EudraCT (2013-003418-42). The study was performed in compliance with ICH Good Clinical Practice (GCP) and the Declaration of Helsinki, including the archiving of essential documents.
All subjects provided written informed consent to participate in the study prior to being screened.
The subject information sheet detailed the procedures involved in the study (aims, methodology, potential risks, anticipated benefits) and the investigator explained these to each subject. Each subject signed the consent form to indicate that the information had been explained and understood. Every subject was then allowed time to consider the information presented before signing and dating the informed consent form to indicate that they fully understood the information, and willingly volunteered to participate in the study.
Before the intake phase, 2 dropouts occured due to acute illness. These subjects were later reincluded after their recovery.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
27 Sep 2016
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Germany: 12
|
||
Worldwide total number of subjects |
12
|
||
EEA total number of subjects |
12
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
12
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
||||||||||||||||
Recruitment
|
||||||||||||||||
Recruitment details |
The study was conducted at University Hospital Tübingen (Germany) at the Department of Sports Medicine. A total of 12 healthy men between 18 and 35 were assessed for eligibility and randomized. No exclusions and 2 dropouts occured. The first participant was enrolled on September 27th, 2016, and the last study visit took place on February 14th, 2018 | |||||||||||||||
Pre-assignment
|
||||||||||||||||
Screening details |
All subjects provided written informed consent to participate prior to being screened. At visit 1 a physical examination took place, vital signs were measured, lactate diagnostics based on spiroergometry were concluded, and blood samples were taken. At visit 2 the randomisation took place. | |||||||||||||||
Period 1
|
||||||||||||||||
Period 1 title |
Visit 2 - 4
|
|||||||||||||||
Is this the baseline period? |
No | |||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||
Blinding used |
Double blind | |||||||||||||||
Roles blinded |
Subject, Investigator, Monitor, Carer, Assessor | |||||||||||||||
Arms
|
||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||
Arm title
|
Verum, Placebo + Training | |||||||||||||||
Arm description |
4500mg magnesium orotate dihydrate per day for 28 days with training. | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
Magnesium orotate dihydrate
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
Magnerot Classic N
|
|||||||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||
Dosage and administration details |
Oral intake of three tablets of 500mg Magnerot Classic N (Magnesium orotate dihydrate), three times per day (=4500mg/d) for 28 days.
|
|||||||||||||||
Arm title
|
Placebo, Verum + Training | |||||||||||||||
Arm description |
Placebo for 28 days, with training | |||||||||||||||
Arm type |
Placebo | |||||||||||||||
Investigational medicinal product name |
Placebo
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||
Dosage and administration details |
Three tablets of placebo, three times per day for 28 days.
|
|||||||||||||||
Arm title
|
Verum, Placebo | |||||||||||||||
Arm description |
4500mg magnesium orotate dihydrate per day for 28 days without training. | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
Magnesium orotate dihydrate
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
Magnerot Classic N
|
|||||||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||
Dosage and administration details |
Oral intake of three tablets of 500mg Magnerot Classic N (Magnesium orotate dihydrate), three times per day (=4500mg/d) for 28 days.
|
|||||||||||||||
Arm title
|
Placebo, Verum | |||||||||||||||
Arm description |
Placebo for 28 days, without training | |||||||||||||||
Arm type |
Placebo | |||||||||||||||
Investigational medicinal product name |
Placebo
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||
Dosage and administration details |
Three tablets of placebo, three times per day for 28 days.
|
|||||||||||||||
|
||||||||||||||||
Period 2
|
||||||||||||||||
Period 2 title |
Visit 6 - 8
|
|||||||||||||||
Is this the baseline period? |
No | |||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||
Blinding used |
Double blind | |||||||||||||||
Roles blinded |
Investigator, Monitor, Subject, Carer, Assessor | |||||||||||||||
Arms
|
||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||
Arm title
|
Verum, Placebo + Training | |||||||||||||||
Arm description |
Placebo for 28 days, with training. | |||||||||||||||
Arm type |
Placebo | |||||||||||||||
Investigational medicinal product name |
Placebo
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||
Dosage and administration details |
Three tablets of placebo, three times per day for 28 days.
|
|||||||||||||||
Arm title
|
Placebo, Verum + Training | |||||||||||||||
Arm description |
4500mg magnesium orotate dihydrate per day for 28 days with training. | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
Magnesium orotate dihydrate
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
Magnerot Classic N
|
|||||||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||
Dosage and administration details |
Oral intake of three tablets of 500mg Magnerot Classic N (Magnesium orotate dihydrate), three times per day (=4500mg/d) for 28 days.
|
|||||||||||||||
Arm title
|
Verum, Placebo | |||||||||||||||
Arm description |
Placebo for 28 days, without training. | |||||||||||||||
Arm type |
Placebo | |||||||||||||||
Investigational medicinal product name |
Placebo
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||
Dosage and administration details |
Three tablets of placebo, three times per day for 28 days.
|
|||||||||||||||
Arm title
|
Placebo, Verum | |||||||||||||||
Arm description |
4500mg magnesium orotate dihydrate per day for 28 days without training. | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
Magnesium orotate dihydrate
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
Magnerot Classic N
|
|||||||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||
Dosage and administration details |
Oral intake of three tablets of 500mg Magnerot Classic N (Magnesium orotate dihydrate), three times per day (=4500mg/d) for 28 days.
|
|||||||||||||||
|
||||||||||||||||
Period 3
|
||||||||||||||||
Period 3 title |
Visit 1
|
|||||||||||||||
Is this the baseline period? |
Yes [1] | |||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||
Blinding used |
Double blind | |||||||||||||||
Roles blinded |
Subject, Investigator, Monitor, Carer, Assessor | |||||||||||||||
Arms
|
||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||
Arm title
|
No Training | |||||||||||||||
Arm description |
Subjects performed no training parallel to the intake of the verum/placebo. | |||||||||||||||
Arm type |
Screening | |||||||||||||||
Investigational medicinal product name |
Magnesium orotate dihydrate
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
Magnerot Classic N
|
|||||||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||
Dosage and administration details |
No intake yet.
|
|||||||||||||||
Investigational medicinal product name |
Placebo
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||
Dosage and administration details |
No intake yet.
|
|||||||||||||||
Arm title
|
Training | |||||||||||||||
Arm description |
Subjects performed aerobic training parallel to the intake of the verum/placebo. | |||||||||||||||
Arm type |
Screening | |||||||||||||||
Investigational medicinal product name |
Magnesium orotate dihydrate
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
Magnerot Classic N
|
|||||||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||
Dosage and administration details |
No intake yet.
|
|||||||||||||||
Investigational medicinal product name |
Placebo
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||
Dosage and administration details |
No intake yet.
|
|||||||||||||||
Notes [1] - Period 1 is not the baseline period. It is expected that period 1 will be the baseline period. Justification: The baseline period was added subsequently as a separate period and could not be set as period 1 due to the system structure. |
||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
No Training
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects performed no training parallel to the intake of the verum/placebo. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Training
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects performed aerobic training parallel to the intake of the verum/placebo. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Verum, Placebo + Training
|
||
Reporting group description |
4500mg magnesium orotate dihydrate per day for 28 days with training. | ||
Reporting group title |
Placebo, Verum + Training
|
||
Reporting group description |
Placebo for 28 days, with training | ||
Reporting group title |
Verum, Placebo
|
||
Reporting group description |
4500mg magnesium orotate dihydrate per day for 28 days without training. | ||
Reporting group title |
Placebo, Verum
|
||
Reporting group description |
Placebo for 28 days, without training | ||
Reporting group title |
Verum, Placebo + Training
|
||
Reporting group description |
Placebo for 28 days, with training. | ||
Reporting group title |
Placebo, Verum + Training
|
||
Reporting group description |
4500mg magnesium orotate dihydrate per day for 28 days with training. | ||
Reporting group title |
Verum, Placebo
|
||
Reporting group description |
Placebo for 28 days, without training. | ||
Reporting group title |
Placebo, Verum
|
||
Reporting group description |
4500mg magnesium orotate dihydrate per day for 28 days without training. | ||
Reporting group title |
No Training
|
||
Reporting group description |
Subjects performed no training parallel to the intake of the verum/placebo. | ||
Reporting group title |
Training
|
||
Reporting group description |
Subjects performed aerobic training parallel to the intake of the verum/placebo. | ||
Subject analysis set title |
Verum
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
Analysis of period with magnesium orotate dihydrate administration
|
||
Subject analysis set title |
Placebo
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
Analysis of period with placebo administration
|
|
|||||||||||||||||||||
End point title |
Delta VO2max | ||||||||||||||||||||
End point description |
Change of maximal oxygen uptake (VO2max) from start to end of period
|
||||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||||
End point timeframe |
start to end of period; between visit 2 and between 4 and visits 6 and 8 respectively
|
||||||||||||||||||||
|
|||||||||||||||||||||
Statistical analysis title |
3-way ANOVA Training v No Training | ||||||||||||||||||||
Statistical analysis description |
3-way variance analysis with fixed effects for medication and training and random effects for subjects. Subject and medication effects are combined. Cross-over design is considered by using intra-individual differences. Period effect and cross-over effects are checked. All parameters are described with descriptive statistcs (sample size, frequency, relative frequency, maximum, minimum, median, standard deviation, 95% confidence interval).
This method was used for all endpoints.
|
||||||||||||||||||||
Comparison groups |
Training v No Training
|
||||||||||||||||||||
Number of subjects included in analysis |
12
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [1] | ||||||||||||||||||||
P-value |
= 0.0789 [2] | ||||||||||||||||||||
Method |
ANOVA | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
Notes [1] - Linear additive mixed model for explanatory data analysis. [2] - 3-way ANOVA |
|||||||||||||||||||||
Statistical analysis title |
3-way ANOVA Verum v Placebo | ||||||||||||||||||||
Statistical analysis description |
3-way variance analysis with fixed effects for medication and training and random effects for subjects. Subject and medication effects are combined. Cross-over design is considered by using intra-individual differences. Period effect and cross-over effects are checked. All parameters are described with descriptive statistcs (sample size, frequency, relative frequency, maximum, minimum, median, standard deviation, 95% confidence interval).
This method was used for all endpoints.
|
||||||||||||||||||||
Comparison groups |
Verum v Placebo
|
||||||||||||||||||||
Number of subjects included in analysis |
24
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other [3] | ||||||||||||||||||||
P-value |
= 0.337 [4] | ||||||||||||||||||||
Method |
ANOVA | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
Notes [3] - Linear additive mixed model for explanatory data analysis. Regarding "number of subjects included": Due to the crossover design the subjects are part of both analyzed groups. Hence, the correct number of subjects included is 12. [4] - 3-way ANOVA |
|
|||||||||||||||||||||
End point title |
Delta AT | ||||||||||||||||||||
End point description |
Change of oxygen uptake (VO2) at anaerobic threshold (AT)
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
start to end of period; between visit 2 and between 4 and visits 6 and 8 respectively
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Delta LT | ||||||||||||||||||||
End point description |
Change of lactate threshold (LT)
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
start to end of period; between visit 2 and between 4 and visits 6 and 8 respectively
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
Delta Pmax | ||||||||||||||||||||
End point description |
Change of maximal power from start to end of period
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
start to end of period; between visit 2 and between 4 and visits 6 and 8 respectively
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
FC MSTN | ||||||||||||||||||||
End point description |
Fold change of muscular myostatin mRNA, log2-transformed (MSTN gene expression)
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Start to end of period; between visit 2 and between 4 and visits 6 and 8 respectively
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
FC LDHB | ||||||||||||||||||||
End point description |
Fold change of muscular lactate dehydrogenase B mRNA, log2-transformed (LDHB gene expression)
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Start to end of period; between visit 2 and between 4 and visits 6 and 8 respectively
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
FC TRIM63 | ||||||||||||||||||||
End point description |
Fold change of muscular Tripartite Motif Containing 63 / muscle-specific RING finger protein 1 mRNA, log2-transformed (TRIM63 gene expression)
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Start to end of period; between visit 2 and between 4 and visits 6 and 8 respectively
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||
End point title |
FC FBXO32 | ||||||||||||||||||||
End point description |
Fold change of period of muscular F-Box Protein 32 / Atrogin-1 mRNA, log2-transformed (FBXO32 gene expression)
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Start to end of period; between visit 2 and between 4 and visits 6 and 8 respectively
|
||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Adverse events were collected from visit 1 until the end of the trial.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
21.1
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Verum
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Reported adverse events during intake of Magnesium orotate dihydrate | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Reported adverse events during intake of placebo | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
08 May 2015 |
Investigator change |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
Small number of patients (pilot study); |